214 related articles for article (PubMed ID: 38315956)
1. Investigating White Matter Neuroinflammation in Alzheimer Disease Using Diffusion-Based Neuroinflammation Imaging.
Wang Q; Schindler SE; Chen G; Mckay NS; McCullough A; Flores S; Liu J; Sun Z; Wang S; Wang W; Hassenstab J; Cruchaga C; Perrin RJ; Fagan AM; Morris JC; Wang Y; Benzinger TLS
Neurology; 2024 Feb; 102(4):e208013. PubMed ID: 38315956
[TBL] [Abstract][Full Text] [Related]
2. Age, vascular disease, and Alzheimer's disease pathologies in amyloid negative elderly adults.
Guo T; Landau SM; Jagust WJ;
Alzheimers Res Ther; 2021 Oct; 13(1):174. PubMed ID: 34654465
[TBL] [Abstract][Full Text] [Related]
3. Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease.
Wang Q; Wang Y; Liu J; Sutphen CL; Cruchaga C; Blazey T; Gordon BA; Su Y; Chen C; Shimony JS; Ances BM; Cairns NJ; Fagan AM; Morris JC; Benzinger TLS
Neuroimage Clin; 2019; 22():101767. PubMed ID: 30901713
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
[TBL] [Abstract][Full Text] [Related]
5. Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer's Disease Continuum.
Chen YH; Lin RR; Huang HF; Xue YY; Tao QQ
Front Aging Neurosci; 2022; 14():848180. PubMed ID: 35847667
[TBL] [Abstract][Full Text] [Related]
6. Association of β-Amyloid, Microglial Activation, Cortical Thickness, and Metabolism in Older Adults Without Dementia.
Cai Y; Shi D; Lan G; Chen L; Jiang Y; Zhou L; Guo T;
Neurology; 2024 Apr; 102(7):e209205. PubMed ID: 38489560
[TBL] [Abstract][Full Text] [Related]
7. Plasma Core Alzheimer's Disease Biomarkers Predict Amyloid Deposition Burden by Positron Emission Tomography in Chinese Individuals with Cognitive Decline.
Ni M; Zhu ZH; Gao F; Dai LB; Lv XY; Wang Q; Zhu XX; Xie JK; Shen Y; Wang SC; Xie Q;
ACS Chem Neurosci; 2023 Jan; 14(1):170-179. PubMed ID: 36547971
[TBL] [Abstract][Full Text] [Related]
8. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
[TBL] [Abstract][Full Text] [Related]
9. Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light.
Schindler SE; Karikari TK; Ashton NJ; Henson RL; Yarasheski KE; West T; Meyer MR; Kirmess KM; Li Y; Saef B; Moulder KL; Bradford D; Fagan AM; Gordon BA; Benzinger TLS; Balls-Berry J; Bateman RJ; Xiong C; Zetterberg H; Blennow K; Morris JC
Neurology; 2022 Jul; 99(3):e245-e257. PubMed ID: 35450967
[TBL] [Abstract][Full Text] [Related]
10. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.
Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC
ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397
[TBL] [Abstract][Full Text] [Related]
11. Baseline Microglial Activation Correlates With Brain Amyloidosis and Longitudinal Cognitive Decline in Alzheimer Disease.
Wang Q; Chen G; Schindler SE; Christensen J; McKay NS; Liu J; Wang S; Sun Z; Hassenstab J; Su Y; Flores S; Hornbeck R; Cash L; Cruchaga C; Fagan AM; Tu Z; Morris JC; Mintun MA; Wang Y; Benzinger TLS
Neurol Neuroimmunol Neuroinflamm; 2022 May; 9(3):. PubMed ID: 35260470
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.
Melah KE; Lu SY; Hoscheidt SM; Alexander AL; Adluru N; Destiche DJ; Carlsson CM; Zetterberg H; Blennow K; Okonkwo OC; Gleason CE; Dowling NM; Bratzke LC; Rowley HA; Sager MA; Asthana S; Johnson SC; Bendlin BB
J Alzheimers Dis; 2016; 50(3):873-86. PubMed ID: 26836182
[TBL] [Abstract][Full Text] [Related]
15. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
[TBL] [Abstract][Full Text] [Related]
16. Exploring the potential of fully automated LUMIPULSE G plasma assays for detecting Alzheimer's disease pathology.
Silva-Spínola A; Leitão MJ; Nadal A; Le Bastard N; Santana I; Baldeiras I
Alzheimers Res Ther; 2024 Mar; 16(1):51. PubMed ID: 38454502
[TBL] [Abstract][Full Text] [Related]
17. CSF Aβ40 and P-Tau181 Might Differentiate Atypical from Typical AD Phenotypes: Preliminary Evidence.
Verde F; Aiello EN; Giacopuzzi Grigoli E; Milone I; Dubini A; Ratti A; Poletti B; Ticozzi N; Silani V
Neurodegener Dis; 2022; 22(2):83-86. PubMed ID: 36108600
[TBL] [Abstract][Full Text] [Related]
18. Race modifies the relationship between cognition and Alzheimer's disease cerebrospinal fluid biomarkers.
Howell JC; Watts KD; Parker MW; Wu J; Kollhoff A; Wingo TS; Dorbin CD; Qiu D; Hu WT
Alzheimers Res Ther; 2017 Nov; 9(1):88. PubMed ID: 29096697
[TBL] [Abstract][Full Text] [Related]
19. Robustness of CSF Aβ42/40 and Aβ42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes.
Leuzy A; Mattsson-Carlgren N; Cullen NC; Stomrud E; Palmqvist S; La Joie R; Iaccarino L; Zetterberg H; Rabinovici G; Blennow K; Janelidze S; Hansson O
Alzheimers Dement; 2023 Jul; 19(7):2994-3004. PubMed ID: 36681387
[TBL] [Abstract][Full Text] [Related]
20. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
